Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women

Dumeaux, Vanessa; Fournier, Agnès; Lund, Eiliv; Clavel‐Chapelon, Françoise

doi:10.1007/s10552-004-8024-z

Cited by 18 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is an example in which functional mapping provides a small set of specific proteins that may serve as regulatory hubs joining two or more interacting pathways. Similarly, while there is a growing understanding of the link between breast and ovarian cancer and hormone stimulus (Dumeaux et al 2005), we predict explicit molecular connections driven by LYN, EIF2B5, and MMS19L. We also observe links between ovarian cancer and other cancers, including breast cancer, osteosarcoma, colorectal cancer, and hepatocellular carcinoma, mainly due to interactions or high microarray correlation with BRCA1, MSH6, and other known cancer-related proteins.…”

Section: Functional Associations: Genetic Disorders and Biological Prmentioning

confidence: 65%

Exploring the human genome with functional maps

Huttenhower¹,

Haley²,

Hibbs³

et al. 2009

Genome Res.

Self Cite

190

249

View full text Add to dashboard Cite

Human genomic data of many types are readily available, but the complexity and scale of human molecular biology make it difficult to integrate this body of data, understand it from a systems level, and apply it to the study of specific pathways or genetic disorders. An investigator could best explore a particular protein, pathway, or disease if given a functional map summarizing the data and interactions most relevant to his or her area of interest. Using a regularized Bayesian integration system, we provide maps of functional activity and interaction networks in over 200 areas of human cellular biology, each including information from ∼30,000 genome-scale experiments pertaining to ∼25,000 human genes. Key to these analyses is the ability to efficiently summarize this large data collection from a variety of biologically informative perspectives: prediction of protein function and functional modules, cross-talk among biological processes, and association of novel genes and pathways with known genetic disorders. In addition to providing maps of each of these areas, we also identify biological processes active in each data set. Experimental investigation of five specific genes, AP3B1, ATP6AP1, BLOC1S1, LAMP2, and RAB11A, has confirmed novel roles for these proteins in the proper initiation of macroautophagy in amino acid-starved human fibroblasts. Our functional maps can be explored using HEFalMp (Human Experimental/Functional Mapper), a web interface allowing interactive visualization and investigation of this large body of information.

show abstract

Section: Functional Associations: Genetic Disorders and Biological Prmentioning

confidence: 65%

Exploring the human genome with functional maps

Huttenhower¹,

Haley²,

Hibbs³

et al. 2009

Genome Res.

Self Cite

190

249

View full text Add to dashboard Cite

show abstract

“…Different studies have defined the risk of breast cancer by evaluation of tumor markers expression and the use of OCP; nevertheless some have reported no significant correlation (13)(14)(15). Overall, there is a mutual agreement on the usefulness of tumor markers (e.g.…”

Section: Discussionmentioning

confidence: 99%

Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: A Case-Control Study

Vahedi¹,

Abdollahzadeh²,

Vaziri³

et al. 2011

Med Oral

View full text Add to dashboard Cite

Objectives: Oral contraceptives (OCP) are highly effective, safe and widely used. Higher exposure to endogenous and exogenous estrogens is generally thought to increase the risk of breast cancer. Therefore, this study was conducted to determine if oral contraceptive use affected the expression of CA 15-3, CEA and C-erb B-2 in the saliva of healthy women. Study design: The participants consisted of 87 healthy women (43 controls and 44 using oral contraceptives) ranging in age from 20 to 54 years. The volunteers participated by giving one -time stimulated whole saliva samples. Then the samples were analysed for CA 15-3, CEA and C-erb B-2 concentrations. Results: The student t-test was used to compare group means for variables with comparable variability. The mean of C-erb B-2, CEA, and CA 15-3 concentrations (in the case and control groups) was (1.93, 1.70), (34.46, 31.62) and (12.58, 16.19) respectively. These differences were not statistically significant. Conclusions: Our findings suggest that the levels of the cancer biomarkers C-erb B-2, CEA and CA 15-3 were not affected by increased levels of estrogens in the body.

show abstract

“…We have previously shown in NOWAC that breast cancer risk increases with the accumulation of the estrogen dose from OCs. 12 An increased risk of breast cancer could have important public health aspects. In this cohort slightly more than one third had ever used OC compared to 70-80% of the female population in younger cohorts in many western countries.…”

Section: Discussionmentioning

confidence: 99%

“…Among 35,449 postmenopausal women 30,118 had complete data for this analysis with 540 incident cases of breast cancer. BMI was divided in 4 groups (<18.5, 18.5-24.9, 25.0-29.9 and 301), family history of breast cancer in mother (yes vs. no), age at menarche (12,(13)(14)151), parity and age at first birth (nulliparous as reference, age at first birth less than 29 years and unipara, age at first birth 30 or more and unipara, and similar for multipara).…”

Section: Methodsmentioning

confidence: 99%

“…[8][9][10][11] One French study looked at current HRT use in relation to previous OC use. 12 They found an additive effect of OC and HRT use on breast cancer risk with no significant interaction. The primary objective of this analysis was to investigate the risk of breast cancer in HRT users taking into account information on former OC use, based on the Norwegian Women and Cancer study (NOWAC).…”

mentioning

confidence: 98%

See 1 more Smart Citation

Hormone replacement therapy and breast cancer in former users of oral contraceptives—The Norwegian Women and Cancer study

Lund

Bakken

Dumeaux

et al. 2007

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Combined estrogen-progestin menopausal therapy (HRT) and combined estrogen-progestin contraceptives (OC) both increase breast cancer risk during current use and a few years after. We investigated risk of breast cancer in women who were users of HRT dependant on former history of OC use in a large, national population-based cohort study, the Norwegian Women and Cancer study (NOWAC). Exposure information was collected through postal questionnaires. Based on follow-up of 30,118 postmenopausal women by linkage to national registers of cancer, deaths, and emigration we revealed 540 incident breast cancer cases between 1996 and 2004. Compared to never users of either drugs current use of HRT gave a significant (p 5 0.002) higher risk of breast cancer in former OC users, RR 5 2.45 (95% CI 1.92-3.12), than among never users of OCs, RR 5 1.67 (1.32-2.12). Relative risk of current use of HRT was similar for estrogen only and combinations with progestin added in ever users of OCs. The increased risk of breast cancer in current HRT users with a history of former OC use could have potential great impact on postmenopausal breast cancer risk as the proportion of postmenopausal women with former OC use will continue to increase. ' 2007 Wiley-Liss, Inc.Key words: breast cancer; OCs; HRT; consecutive use; NOWAC Combined estrogen-progestin menopausal therapy and combined estrogen-progestin contraceptives have both been classified as carcinogenic to humans (Group 1). 1 The increased risk of 30-40% for breast cancer related to OC use is mainly connected to present and recent use, while for HRT use the risk also increases with duration of use. [2][3][4][5] For HRT use the increased risk of 1.26 was somewhat lower in the clinical trial of Women's Health Initiative 6 than in most epidemiological studies with relative risks around 2. This could partly be due to the use of different combinations of hormones. During the last decade an increasing number of former OC users have reached the menopausal age, estimated to around 300 million worldwide and exceeding 80% in some moredeveloped countries. 1 Use of treatment with HRT peaked around 2000 with about 20 million women in more-developed countries using this therapy, including as much as half of the women in US aged 50-64 years. 1 Since then use has been substantially reduced. With 1 million cases diagnosed in the world annually, breast cancer is by far the most common female cancer, comprising about 20% of all new cancers in women. 7 Among the few studies that have looked at risk related to combined use of both OCs and HRT, most studies have limited the analyses to ever use of HRT. [8][9][10][11] One French study looked at current HRT use in relation to previous OC use. 12 They found an additive effect of OC and HRT use on breast cancer risk with no significant interaction. The primary objective of this analysis was to investigate the risk of breast cancer in HRT users taking into account information on former OC use, based on the Norwegian Women and Cancer study (NOWAC). Material and meth...

show abstract

Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women

Cited by 18 publications

References 38 publications

Exploring the human genome with functional maps

Exploring the human genome with functional maps

Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: A Case-Control Study

Hormone replacement therapy and breast cancer in former users of oral contraceptives—The Norwegian Women and Cancer study

Contact Info

Product

Resources

About